HOLX - Hologic, Inc.
40.33 0.00 (0.00%)
After hours: 4:31PM EST
| Previous Close | 40.97 |
| Open | 41.00 |
| Bid | 38.00 x 1200 |
| Ask | 48.00 x 800 |
| Day's Range | 40.12 - 41.46 |
| 52 Week Range | 35.10 - 45.09 |
| Volume | 1,865,091 |
| Avg. Volume | 2,070,261 |
| Market Cap | 10.975B |
| Beta (3Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Feb 6, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.03 |
- CNBC Videos•last month
Hologic CEO on fighting breast cancer
As Breast Cancer Awareness Month kicks off, Hologic CEO Steve MacMillan speaks to "Squawk Box" about the company's new imaging tech to better help detect cancer.
Markit•4 days agoSee what the IHS Markit Score report has to say about Hologic Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- GlobeNewswire•4 days ago
Recent Analysis Shows The Mosaic, National Health Investors, Capital Senior Living, Independence Contract Drilling, Hologic, and TrueBlue Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of HOLX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q4 2018 Hologic Inc Earnings Call
- Zacks•5 days ago
Hologic (HOLX) Q4 Earnings Miss, Revenues Top Estimates
Tough year-over-year comparisons and soft Diagnostics sales hurt Hologic's (HOLX) performance in Q4.
Motley Fool•6 days agoHologic, Inc. (HOLX) Q4 2018 Earnings Conference Call Transcript
HOLX earnings call for the period ending September 30, 2018.
- Zacks•6 days ago
Hologic (HOLX) Misses Q4 Earnings Estimates
Hologic (HOLX) delivered earnings and revenue surprises of -1.69% and 1.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•6 days ago
Hologic: Fiscal 4Q Earnings Snapshot
MARLBOROUGH, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported fiscal fourth-quarter profit of $50.5 million. The Marlborough, Massachusetts-based company said it had profit of 18 cents per share. The results fell short of Wall Street expectations.
- Business Wire•6 days ago
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2018
– Revenue of $813.5 Million Grows 1.3%, 1.7% in Constant Currency –
- Business Wire•7 days ago
Hologic to Webcast Presentation at the Stifel 2018 Healthcare Conference
Hologic, Inc. announced today that the Company will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13 at 8 a.m. Eastern Time.
- Zacks•12 days ago
What's Setting the Tone for Hologic's (HOLX) Q4 Earnings?
Strength in the Breast Health business, Panther system and increasing utilization of Aptima women's health assays will boost Hologic's (HOLX) top line in Q4.
Markit•20 days agoSee what the IHS Markit Score report has to say about Hologic Inc.
Hologic Inc NASDAQ/NGS:HOLX
- GlobeNewswire•28 days ago
Report: Exploring Fundamental Drivers Behind Inovalon, Evolent Health, Limoneira, Overstock, Hologic, and Reading International — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•last month
Calculating The Fair Value Of Hologic Inc (NASDAQ:HOLX)
In this article I am going to calculate the intrinsic value of Hologic Inc (NASDAQ:HOLX) by projecting its future cash flows and then discounting them to today’s value. I will Read More...
- Business Wire•last month
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2018 on Wednesday, November 7, 2018
Hologic, Inc. announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2018 on Wednesday, November 7, 2018, after the market closes.
- PR Newswire•last month
Hologic Survey Reveals More than Three in Five Women are Unaware that the Density of a Woman's Breasts Impacts Her Risk for Developing Breast Cancer
Survey commissioned by Company behind the Genius™ 3D Mammography™ exam sheds light on need for education during Breast Cancer Awareness Month MARLBOROUGH, Mass. , Oct. 1, 2018 /PRNewswire/ -- WHO: ...
- Zacks•2 months ago
Women Health a Prime Concern Worldwide: 3 Stocks in Focus
Women health care gradually gaining importance globally, investors might keep an eye on a few stocks.
- Business Wire•2 months ago
Hologic CEO Steve MacMillan to be Joined by Susan G. Komen Founder Nancy Brinker and Pink Hope Founder Krystal Barter to Ring Nasdaq Opening Bell on October 1
Hologic, Inc. (HOLX) announced today that Nancy G. Brinker, global cancer advocate, Hologic consultant and founder of Susan G. Komen, and Krystal Barter, author and founder of Australian nonprofit Pink Hope, will join Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, and selected employees to ring the Nasdaq Opening Bell for the 13th consecutive year on October 1 to mark the start of Breast Cancer Awareness Month. In addition to appearing at the Nasdaq MarketSite, Hologic will recognize Breast Cancer Awareness Month by announcing the results from their recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the effect it has on breast cancer screening and cancer detection.
- Zacks•2 months ago
Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
- Benzinga•2 months ago
The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 26) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
- Business Wire•2 months ago
Hologic to Acquire Focal Therapeutics for $125 Million, Strengthening Breast Surgery Franchise
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic’s recent acquisition of Faxitron Bioptics, Focal strengthens the Company’s position in the rapidly growing market for breast conserving surgery. The transaction adds Focal’s innovative BioZorb marker to the Company’s Breast Health product portfolio.
Markit•2 months agoSee what the IHS Markit Score report has to say about Hologic Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding HOLX is favorable, with net inflows of $27.64 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Market Realist•2 months agoCynosure Headwinds Trigger Analyst Downgrades on HOLX Stock
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. ...
Market Realist•2 months agoHologic’s Cynosure Headwinds Could Impact 2018 Earnings
On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes, which it announced in August. The company issued form 8-k on August 13 reporting its decision to suspend the marketing and distribution of the company’s Tempsure Vitalia handpieces and probes. The device, part of the company’s Cynosure division, was recalled on FDA (U.S. Food and Drug Administration) concerns around this class of products, which are used for vaginal rejuvenation procedures. The FDA sent letters to certain companies that manufactured these kinds of devices.
